GlaxoSmithKline SAE operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares GlaxoSmithKline SAE with three other
pharmaceutical manufacturers in Middle East:
Hayat Pharmaceutical Industries Company PSC
sales of 15.64 million Jordanian Dinars [US$22.06 million]
Alexandria Pharmaceuticals and Chemical Industries Co
(750.00 million Egyptian Pounds [US$46.89 million]
Dar Al Dawa Development and Investment Company PSC
based in JORDAN
(54.86 million Jordanian Dinars [US$77.38 million]
of which 75%
During the year ended December of 2019, sales at
GlaxoSmithKline SAE were 1.70 billion Egyptian Pounds (US$106.54 million).
increase of 5.0%
versus 2018, when the company's sales were 1.62 billion Egyptian Pounds.
This was the fourth straight year of sales growth at GlaxoSmithKline SAE.
Sales of Consumer Care Sector saw an increase
that was more than double the company's growth rate: sales were up
34.9% in 2019, from
242.13 million Egyptian Pounds to 326.53 million Egyptian Pounds.
Not all segments of GlaxoSmithKline SAE experienced an increase in sales in 2019:
sales of Medical Sector fell 0.3% to 1.38 billion Egyptian Pounds.